NBIX - CIK 0000914475
NEUROCRINE BIOSCIENCES INC trades as NBIX and has a market capitalization of $16.17 B, making it the #700 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $2.86B, up 21.4% from the prior year and net income of $478.60M. This page tracks NEUROCRINE BIOSCIENCES INC through 2,097 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 9 fiscal years NEUROCRINE BIOSCIENCES INC's revenue grew from $15.00M to $2.86B, a compound annual growth rate of 79.2%. Net profit margin expanded from -940.6% to 16.7% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| Insider sale notice | 144 | 2026-05-26 |
| Insider trade | 4 | 2026-05-21 |
| Insider trade | 4 | 2026-05-21 |
| Insider trade | 4 | 2026-05-21 |
| Insider trade | 4 | 2026-05-21 |
| Insider trade | 4 | 2026-05-21 |
| Insider trade | 4 | 2026-05-21 |
| Insider trade | 4 | 2026-05-21 |
Neurocrine Biosciences Presents Real-World Data Highlighting Functional Impact of Mild Tardive Dyskinesia Severity and Improvement with INGREZZA® (valbenazine) Capsules | Neurocrine Biosciences
Neurocrine Biosciences Completes Acquisition of Soleno Therapeutics | Neurocrine Biosciences
Neurocrine Biosciences Announces Publication of Expert Recommendations for Glucocorticoid Dose Reduction after Initiating CRENESSITY® (crinecerfont) for the Treatment of Classic Congenital Adrenal Hyperplasia | Neurocrine Biosciences
Neurocrine Biosciences Reports First-Quarter 2026 Financial Results | Neurocrine Biosciences
Neurocrine Biosciences to Present at the Bank of America Health Care Conference 2026 | Neurocrine Biosciences
The largest companies sharing NEUROCRINE BIOSCIENCES INC's SEC industry classification (biological products, (no diagnostic substances)).
NEUROCRINE BIOSCIENCES INC (NBIX) has a market capitalization of $16.17 B as of 2026-06-10, ranking #700 among US-listed companies.
NEUROCRINE BIOSCIENCES INC reported revenue of $2.86B for fiscal year 2025, an increase of 21.4% year over year.
Yes. NEUROCRINE BIOSCIENCES INC reported net income of $478.60M in its latest fiscal year.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.